AMIKACIN SULFATE

Post-LOE

amikacin sulfate

Bristol Myers Squibb

ANDAINJECTIONINJECTABLE

Approved

Dec 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMIKACIN SULFATE (amikacin sulfate) by Bristol Myers Squibb is clinical pharmacology intramuscular administration amikacin is rapidly absorbed after intramuscular administration. Approved for the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli and 12 more indications. First approved in 2013.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Intramuscular Administration Amikacin is rapidly absorbed after intramuscular administration. In normal adult volunteers, average peak serum concentrations of about 12, 16, and 21 mcg/mL are obtained 1 hour after intramuscular administration of 250 mg (3.7 mg/kg), 375 mg (5…

Worked on AMIKACIN SULFATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

AMIKACIN SULFATE

Mechanism of Action

Indications (15)